Adaptive hypersensitivity to estradiol: Potential mechanism for secondary hormonal responses in breast cancer patients

Journal of Steroid Biochemistry and Molecular Biology

Volumn 79, Issue 1-5, 2001, Pages 115-125

  Santen, Richard ^a   Jeng, Meei Huey ^b   Wang, Ji Ping ^a   Song, Robert ^a   Masamura, Shigeru ^c   McPherson, Robert ^a   Santner, Steven ^d   Yue, Wei ^a   Shim, Woo Shin ^e  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b INDIANA UNIVERSITY   (United States)

^c KEIO UNIVERSITY   (Japan)

^d KARMANOS CANCER INSTITUTE   (United States)

^e Gachon University College of Medicine   (South Korea)

Author keywords

Aromatase; Breast cancer; Estrogen; Hypersensitivity; MAP kinase; Non genomic estrogen effects; Proliferation

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTIESTROGEN; CANCER GROWTH FACTOR; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; GROWTH FACTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; HORMONE; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROTEIN PGR; PROTEIN PS2; PROTEIN SHC; RAF PROTEIN; RAS PROTEIN; SOS PROTEIN; UNCLASSIFIED DRUG;

BREAST CARCINOMA; CELL LINE; CELL MEMBRANE; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFECT; DRUG HYPERSENSITIVITY; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; ENZYME ACTIVITY; HORMONE RESPONSE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; WILD TYPE;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; PROTEINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0035714726     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(01)00151-0     Document Type: Conference Paper

References (60)

1. Cancer statistics
2. Endocrine treatment of breast cancer in women
3. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma
4. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer
5. Tamoxifen for early breast cancer: An overview of the randomized trials
6. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph modes and estrogen receptor-positive tumors
7. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer: The Scottish Cancer Trials Breast Group
8. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens
9. Long term tamoxifen therapy: Can an antagonist become an agonist?
10. When tamoxifen turns bad
11. Estrogen deprivation causes estradiol hypersensitivity in human cancer cells
12. Higher levels of control: Modulation of steroid hormone-regulated gene transcription
13. Identification of a negative regulatory function for steroid receptors
14. Differential regulation by estrogens of growth and prolactin synthesis in pituitary cells suggests that only a small pool of estrogen receptors is required for growth
15. A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells
16. Low androgen levels induce the development of androgen-hypersensitive cell clones in Shionogi mouse mammary carcinoma cells in culture
17. Changing sensitivity of the pubertal hypothalamic feedback mechanism in man
18. Perturbations of negative feedback sensitivity in agonadal patients undergoing estrogen replacement therapy
19. The endocrine basis of seasonal reproductive function in the ewe: A marked change in response to the negative feedback action of estradiol on luteinizing hormone secretion
20. Prolonged negative feedback suppression after estradiol administration: Proposed mechanism of eugonadal secondary amenorrhea
21. Identification of a novel transferable cis element in the promoter of an estrogen-responsive gene that modulates sensitivity to hormone and antihormone
22. Modulation of TAT gene induction by glucocorticoids involves a neutralizing sequence
23. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
24. Vorozole (Rivizor™) versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen
25. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
26. Use of aromatase inhibitors in breast carcinoma
27. Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture
28. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications
29. Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo
30. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cell lines grown in the short-term and long-term absence of estrogens
31. Alterations in transforming growth factor -α and -β production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth
32. Differential regulation of gene expression by estrogen in estrogen-growth independent and -dependent MCF-7 human breast cancer cell sublines
33. Characterization of a receptor-negative, hormone-unresponsive clone derived from a T-47-D human breast cancer cell line kept under estrogen-free conditions
34. Cellular and molecular events in loss of estrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells
35. The control of hormone dependent breast cancer - Are we talking about estrogen alone
36. Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer
37. Activation of MAP kinase in estrogen dependent human breast cancer cells during regrowth in the absence of exogenous estrogen
38. Estradiol hypersensitivity and MAP kinase expression in long term estrogen deprived human breast cancer cells in vivo
39. Enhanced androgen sensitivity in serum-free medium of a subline of the LnCAP human prostate cancer cell line
40. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation
41. Progression of LnCAP prostate tumor cells during androgen deprivation: Hormone-independent growth, repression of proliferation by androgen, and role for p27kip1 in androgen-induced cell cycle arrest
42. Endocrine treatment of prostate cancer
43. P-nonyl-phenol: An estrogenic xenobiotic released from modified polystyrene
44. The E-SCREEN assay as a tool to identify estrogens: An update on estrogenic environmental pollutants
45. bis-Phenol-A: An estrogenic substance is released from polycarbonate flasks during autoclaving
46. Estrogenic effects of nonylphenol on PS2, ER and MUC1 gene expression in human breast cancer cells - MCF-7
47. Hydroxylated polychlorinated biphenyls (PCBS) as estrogens and antiestrogens-structure-activity relationships
48. Growth factors in breast cancer
49. Convergence of progesterone and epidermal growth factor signaling in breast cancer-potentiation of mitogen-activated protein kinase pathways
50. Prognostic factors in breast cancer
51. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
52. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation
53. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells
54. Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells
55. Myc and Ras collaborate in inducing accumulation of active cycling E/Cdk2 and E2F
56. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F
57. Inhibition of c-myc expression by phosphorothioate antisense olingonucletide identifies a critical role for c-myc in the growth of human breast cancer
58. Cell cycle events associated with the ability of hormone dependent breast cancer cells to grow in the absence of exogenous estrogen
59. SHC phosphorylation and interaction with ER alpha are required for estrogen-induced MAP kinase phosphorylation in MCF-7 human breast cancer cells